Sangamo Therapeutics Inc. (SGMO)
Symbol Info
Listed Symbol SGMO
Name Sangamo Therapeutics Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $84,452,000
Latest Fiscal EPS $-0.71
Price Info
21 Day Moving Average $11.0052
21 Day EMA $11.007360
50 Day Moving Average $11.4288
50 Day EMA $11.078010
200 Day EMA $11.437210
200 Day Moving Average 10.799700
52 Week High $17.35
52 Week Low $6.26
52 Week Change $-26.440700
Alpha -0.002585
Beta 2.8008
Standard Deviation 0.198138
R2 0.237498
Periods 60
Share Information
10 Day Average Volume 940,200
20 Day Average Volume 1,009,471
30 Day Average Volume 1,219,028
50 Day Average Volume 1,743,910
Outstanding Shares 115,675,077
Float Shares 113,597,471
Percent Float 98.20%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 382
Institute Holdings Date 2019-08-31
Institute Bought Previous 3 Months 20,925,588
Institute Holdings Percent 98.400000
Institute Sold Previous 3 Months 6,482,762
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 14
Insider Holdings Percent 1.80%
Insider Sold Previous 3 Months -
Insiders Shares Owned 2,077,606
Price Change
7 Day Price Change $0.2300005
7 Day Percent Change 2.17%
21 Day Price Change $-0.1700001
21 Day Percent Change -1.54%
30 Day Price Change $-0.5899992
30 Day Percent Change -5.16%
Month To Date Price Change $-0.05
Month To Date Percent -0.46%
90 Day Price Change $1.250000
90 Day Percent Change 13.02%
Quarter To Date $0.080000
Quarter To Date Percent 0.74%
180 Day Price Change $0.750000
180 Day Percent Change 7.43%
200 Day Price Change $1.820001
200 Day Percent Change 20.16%
Year To Date $-0.629999
Year To Date Percent -5.49%
Profile
Description Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.
Details
Issue Type CS
Market Cap $1,255,074,585
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 115,675,077
CEO Alexander Macrae
Employees 302
Last Audit UE
Classification
CIK 0001001233
Industry Biotechnology
Sector Healthcare
NAICS Biological Product (except Diagnostic) Manufacturing(325414)
Info
Address 501 Canal Boulevard
Richmond, CA 94804
Website https://www.sangamo.com
Facisimile +1 510 236-8951
Telephone +1 510 970-6000
Email mstilwell@sangamo.com
Key Ratios
Profitability
EBIT Margin -150.5
EBITDA Margin -146.9
Pre-Tax Profit Margin -155.1
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $76,018,000
Revenue Per Share $0.6572
Revenue 3 Years $53.48
Revenue 5 Years $13.97
Valuation Measures
PE Ratio -
Enterprise Value $885,601,105
Price To Sales 16.510231
Price To Free Cash -4.7
PE High Last 5 Years -
Price To Book 2.9
Price To Cash Flow 119.2
PE Low Last 5 Years -
Price To Tangible Book 3.7
Financial Strength
Total Debt To Equity 0.1
Int Coverage -
Current Ratio 5.6
Leverage Ratio 1.6
Quick Ratio 5.5
Long Term Debt To Capital 0.09
Assets
Receivables Turnover 5.1
Invoice Turnover -
Assets Turnover 0.10
Management Effectiveness
Return Assets -15.98
Return On Equity -24.96
Return On Capital -23.08
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
SGMO
Sangamo Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.